Guselkumab for hidradenitis suppurativa: a phase II, open-label, mode-of-action study.
Dudink K, Bouwman K, Chen Y, DePrimo SE, Munoz-Elias EJ, Aarts P, Schappin R, Florencia EF, van Heeswijk B, Prens LM, van der Zee HH, Prens EP, van Straalen KR, Horváth B.
Dudink K, et al. Among authors: schappin r.
Br J Dermatol. 2023 Apr 20;188(5):601-609. doi: 10.1093/bjd/ljad010.
Br J Dermatol. 2023.
PMID: 36811949
Clinical Trial.